Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders

Inflammatory Bowel Diseases

Volumn 15, Issue 11, 2009, Pages 1630-1634

  Jeffery, Jinny ^a   Lewis, Stephen J ^a   Ayling, Ruth M ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

Calprotectin; Crohn's disease; Inflammatory bowel disease; Tumor M2 PK

Indexed keywords

CALGRANULIN; PYRUVATE KINASE; PYRUVATE KINASE ISOENZYME M 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ENTEROPATHY; FECES ANALYSIS; FEMALE; HUMAN; INTESTINE ENDOSCOPY; INTESTINE FUNCTION DISORDER; INTESTINE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHEMISTRY, CLINICAL; DIAGNOSIS, DIFFERENTIAL; DIMERIZATION; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; ISOMERISM; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PYRUVATE KINASE; ROC CURVE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 72549091266     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20946     Document Type: Article

References (23)

1. Mazurek S, Boschek CB, Hugo F, et al. Pyruvate kinase type M2 and its role in tumour growth and spreading. Semin Cancer Biol. 2005;15:300-308. (Pubitemid 41058775)
2. Hardt PD, Ngoumou BK, Rupp J, et al. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastrointestinal cancer. Anticancer Res. 2000;20:4965-4968.
3. Hoopmann M, Warm M, Mallmann P, et al. Tumor M2 pyruvate kinase: determination in breast cancer patients receiving trastuzumab therapy. Cancer Lett. 2002;187:223-228.
4. Schneider J, Neu K, Grimm H, et al. Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res. 2002;22:311-318. (Pubitemid 34475318)
5. Oremek GM, Teigelkamp S, Kramer W, et al. The pyruvate kinase isoenzyme tumour M2 (Tu M2PK) as a tumour marker for renal carcinoma. Anticancer Res. 1999;19:2599-2601. (Pubitemid 29392419)
6. Oremek GM, Muller R, Sapoutzis N, et al. Pyruvate kinase type tumour M2 plasma levels in patients afflicted with rheumatic diseases. Anticancer Res. 2003;23:1131-1134. (Pubitemid 36750929)
7. Hard PD, Mazurka S, Toepler M, et al. Fecal tumor M2 pyruvate kinase: a new sensitive screening tool for colorectal cancer. Br J Cancer. 2004;91:980-984. (Pubitemid 39273794)
8. Tonus C, Neupert G, Sellinger M. Colorectal cancer screening by non-invasive metabolic biomarker fecal tumour M2-PK. World J Gastroenterol. 2006;12:7007-7011. (Pubitemid 44834892)
9. Koss K, Maxton D, Jankowski JA. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Colorectal Dis. 2008;10:244-248.
10. Tibble J, Sigthorsson G, Foster R, et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49:402-408. (Pubitemid 32802576)
11. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin a novel granulocyte marker protein. Digestion.1997:58:176-180.
12. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing inflammation in Crohn's disease. Gut. 2000;47:506-513.
13. Fagerberg UL, Loof U, Myrdal U, et al. Colorectal inflammation is well predicted by faecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005;40:450-455. (Pubitemid 40489572)
14. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gatroenterology. 2000;119:15-22. (Pubitemid 30452574)
15. Chung-Faye G, Hayee B, Maestranzi S, et al. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm Bowel Dis. 2007;13:1374-1378. (Pubitemid 350206848)
16. Czub E, Herzig KH, Szaflarska-Popawska A, et al. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1147-1150.
17. Bjarnason I, Macpherson AJM, Hayllar J. Intestinal permeability: an overview. Gastroenterology. 1995;108:1566-1581.
18. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377-1390.
19. Jones J, Boorman J, Cann P, et al. British Society of Gastroenterology guidelines for the management of irritable bowel syndrome. http://www.bsg.org. uk/guidelines.
20. Hommes DW, van Deventer SJ. Endoscopy in inflammatory bowel diseases. Gastroenterology. 2004;126:1561-1573.
21. Angriman I, Scarpa M, D'Inca R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007;381:63-68. (Pubitemid 46719135)
22. Walkowiak J, Banasiewicz T, Krokowicz P, et al. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis. Scand J Gastroenterol. 2005;40:1493-1494. (Pubitemid 43028212)
23. D'Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007;22:429-437. (Pubitemid 46336248)